This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Storrs, R. C. Articles by Hananian, J. Search for Related Content PubMed PubMed Citation Articles by Storrs, R. C. Articles by Hananian, J.

Remission Maintenance in Acute Lymphocytic Leukemia with Hydroxyurea¹

Hitchcock Hospital, Dartmouth Medical School, Hanover, New Hampshire (R. C. S.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (I. J. W.), Maimonides Hospital of Brooklyn and Long Island Jewish Hospital, New York (B. D. G.), and Roswell Park Memorial Institute, Buffalo, New York (J. H.)

After complete remission had been induced by prednisone and vincristine in children with acute leukemia, hydroxyurea was used in an effort to maintain remission. No significant prolongation of remission occurred despite the appearance of toxicity in over 50% of the high dosage group. An equally significant observation was that the duration of remission produced by prednisone and vincristine was longer in those who had not received vincristine during a prior induced remission.

¹ This study was undertaken by the Acute Leukemia Cooperative Group B (Chairman, James F. Holland) and was supported by Public Health Service Research Grants from the National Cancer Institute. Other participating members of the Group are: Mount Sinai Hospital, New York, New York; Bowman Gray School of Medicine, Winston-Salem, North Carolina; University of Miami Medical School, Miami, Florida; Rhode Island Hospital, Providence, Rhode Island; and Mayo Clinic, Rochester, Minnesota.

² This work was supported by Grant CA-04326 (R.C.S.), Grant CA-04737 (I.J.W.), Grant CA-05923 (B.D.G.), and Grant CA-07918 (J.H.).

Received 3/19/65. Revised 8/18/65.